TIDMSYNC
RNS Number : 1833R
Syncona Limited
04 March 2021
Syncona Limited
Autolus Reports Full Year 2020 Financial Results and Operational
Progress
04 March 2021
Syncona Ltd, a leading healthcare company focused on founding,
building and funding a portfolio of global leaders in life science,
notes that its portfolio company, Autolus Therapeutics Plc (NASDAQ:
AUTL) (Autolus), announced its financial results for the fourth
quarter and full year ended December 31, 2020.
The announcement can be accessed on Autolus' investor website at
https://www.autolus.com/investor-relations and full text of the
announcement from Autolus is contained below. Autolus management
will host a conference call today, at 8:30 a.m. EDT/ 1:30pm GMT to
discuss the company's financial results and operational update. To
listen to the webcast and view the accompanying slide presentation,
please go to:
https://www.autolus.com/investor-relations/news-and-events/events
.
[S]
Enquiries
Syncona Ltd
Annabel Clay
Tel: +44 (0) 20 3981 7940
FTI Consulting
Ben Atwell / Natalie Garland-Collins / Tim Stamper
Tel: +44 (0) 20 3727 1000
About Syncona
Syncona's purpose is to invest to extend and enhance human life.
We do this by founding, building and funding a portfolio of global
leaders in life science, to deliver transformational treatments to
patients in areas of high unmet need.
Our strategy is to found, build and fund companies around
exceptional science to create a dynamic portfolio of 15-20 globally
leading healthcare businesses for the benefit of all our
stakeholders. We focus on developing treatments for patients by
working in close partnership with world-class academic founders and
management teams. Our strategic balance sheet underpins our
strategy enabling us to take a long-term view as we look to improve
the lives of patients with no or few treatment options, build
sustainable life science companies and deliver strong risk-adjusted
returns to shareholders.
Autolus Therapeutics Reports Fourth Quarter and Full Year 2020
Financial Results and Operational Progress
- Conference call to be held on March 4, 2021 at 8:30 am ET/1:30
pm GMT -
LONDON , March 4, 2021 -- Autolus Therapeutics plc (Nasdaq:
AUTL), a clinical-stage biopharmaceutical company developing
next-generation programmed T cell therapies, today announced its
operational and financial results for the fourth quarter and full
year ended December 31, 2020.
"Autolus' primary focus is on delivering the potential pivotal
AUTO1 program and the company starts 2021 in a position of
financial strength, having raised a total of $131 million in gross
proceeds this quarter, giving us a cash runway into the first half
of 2023," said Dr. Christian Itin, chairman and chief executive
officer of Autolus. "We are excited about the unique
characteristics of AUTO1 and the significant commercial opportunity
that adult Acute Lymphoblastic Leukemia represents. Furthermore, we
are committed to building additional value by capitalizing on the
unique clinical profile of AUTO1 in additional B Cell malignancies
and by progressing our pipeline of CAR T cell therapies, including
AUTO1/22 in pediatric ALL, AUTO4 in peripheral T cell Lymphoma and
AUTO6NG in solid tumors. As such, we expect multiple clinical proof
of concept read outs during 2021 and 2022."
Key Pipeline Updates:
-- AUTO1 in relapsed / refractory (r/r) adult B-Acute
Lymphocytic Leukemia (ALL) . Positive data from the ALLCAR Phase 1
clinical trial was presented at the 62(nd) American Society of
Hematology (ASH) Annual Meeting in December 2020, demonstrating
that, as of the November 12, 2020 data cut-off date, AUTO1 was well
tolerated, with no patients experiencing >= Grade 3 cytokine
release syndrome (CRS). Three patients (15%), all of whom had high
leukemia burden (>50% blasts), experienced Grade 3 neurotoxicity
(NT) that resolved swiftly with steroids. Of the 19 patients
evaluable for efficacy, 16 (84%) patients achieved minimum residual
disease (MRD)-negative complete response (CR) at one month. Most
notably, the durability of remissions is highly encouraging. Across
all treated patients, event free survival (EFS) at six and 12
months is 69% and 52% respectively. Median EFS and overall survival
(OS) had not been reached at a median follow up of 16.9 months
(range up to 30.5 months). Data from the potential pivotal program,
FELIX, is expected in 2022.
-- AUTO1 in indolent B cell Non-Hodgkin Lymphoma (NHL) (cohort
1), high grade B-NHL (cohort 2) and chronic lymphocytic leukemia
(CLL) (cohort 3). Autolus reported positive AUTO1 data at the
62(nd) American Society of Hematology (ASH) Annual Meeting in
December 2020. As of the data cut-off date of November 12, 2020,
four patients in Cohort 1 had been infused with AUTO1. AUTO1 was
well tolerated, with no patients experiencing >= Grade 2 CRS and
no patients experiencing NT of any grade. All four patients
achieved a Complete Metabolic Response (CMR). Autolus is planning
to present updated data on AUTO1 in indolent B-cell lymphoma
indications at the European Hematology Association (EHA) Congress
in June 2021.
-- AUTO1/22 in pediatric ALL . The first patient was dosed in
the extension cohort of the CARPALL clinical trial in Q4 2020 .
Autolus plans to provide a data update in Q4 2021.
-- AUTO3 in relapsed/refractory diffuse large B cell lymphoma
(DLBCL). Positive data from the Phase 1 ALEXANDER clinical trial
was presented at the 62nd American Society of Hematology (ASH)
Annual Meeting in December 2020 demonstrating, as of the October
30, 2020 data cut-off date, AUTO3 was well tolerated, with low
rates of CRS and NT. Across all 49 patients, there was only one
case of Grade 3 CRS with primary infusion, and only three cases of
NT were reported, with two being >= Grade 3. As of the data
cut-off date, none of the patients achieving a complete response
(CR) experienced any NT and all cases of NT observed were seen in a
setting of disease progression and with confounding factors.
Autolus plans to seek a partner for this program.
-- AUTO4 in Peripheral T Cell Lymphoma (PTCL). AUTO4 will
continue, in 2021, to be evaluated in a dose escalation phase of a
Phase 1/2 clinical trial in 2021. Autolus expects to provide a next
data update in H2 2021.
-- AUTO5 in Peripheral T Cell Lymphoma . Positive preclinical
data were presented at the American Association for Cancer Research
II (AACR) Annual Meeting in June 2020. The data highlight the
specificity and selectivity of the Autolus T cell lymphoma product
candidate, AUTO5. Autolus expects to initiate a Phase 1 clinical
trial in H2 2021.
-- AUTO6NG in small cell lung cancer (SCLC). Positive
preclinical data were presented at the AACR Annual Meeting in June
2020. Autolus has designed enhancing modules to specifically
overcome tumor microenvironment (TME) defenses in solid tumor
settings. The new data reported at the AACR meeting suggest that
AUTO6NG can overcome the immune suppressive mechanisms in the TME.
Autolus plans to progress AUTO6NG for evaluation in GD2 positive
tumors into the clinic in H2 2021.
-- AUTO7 in prostate cancer . Positive preclinical data were
presented at an oral presentation at the AACR Annual Meeting in
June 2020. AUTO7 uses an optimized CAR to target cancer cells
expressing PSMA, even at low levels, and includes modules
introduced in AUTO6NG, with a module that activates immune
responses at the tumor site through limited secretion of IL-12. The
data presented at the AACR meeting demonstrated that AUTO7 is
highly potent in cytotoxicity assays against cells expressing PSMA,
even at low levels, and demonstrate the feasibility of this
multi-modular cell programming approach in overcoming the
immunotherapeutic challenges presented by advanced prostate cancer,
which is typically otherwise an immunologically cold tumor. Autolus
plans to progress AUTO7 into the clinic in H1 2022.
-- AUTO8 in multiple myeloma. This program will be explored in a
first clinical trial starting mid-2021.
-- Partnerable Coronavirus Disease (COVID-19) Project . Autolus'
research team has developed a potentially universal SARS-CoV2 decoy
receptor with virus neutralizing activity against SARS-CoV2 and its
variants and also active against SARS-CoV1.
Operational Highlights:
-- Autolus sold 1,718,506 ADSs under its at-the-market program
with Jefferies, for net proceeds of approximately $15.3 million, in
January 2021.
-- Successful closing of a public offering raising net proceeds
to Autolus, after underwriting discounts and commissions, of $108.1
million in February 2021, taking total net cash raised in Q1 2021
to approximately $123.4 million.
-- As announced in Autolus' business update in January 2021, the
company will be prioritizing the AUTO1 program and plans to partner
the AUTO3 program before progressing it into the next phase of
development.
-- Also announced in Autolus' business update in January 2021,
the company will adjust its workforce and infrastructure footprint,
which will involve an overall reduction in headcount of
approximately 20%. The restructuring remains ongoing and Autolus
expects to realize cash savings, on an annualized basis, of
approximately $15 million per annum once the operational changes
are fully implemented.
-- As previously announced, Dr. Nushmia Khokhar, Senior Vice
President, Clinical Development will be leaving the company in
mid-March 2021 and Dr. Adam Hacker, Senior Vice President for
Regulatory Affairs and Quality, left the Company in January 2021.
The company would like to thank Drs. Khokhar and Hacker for their
contributions and wishes them well in the future. A search for a
Chief Medical Officer is ongoing.
-- Appointment of Dr Jay T Backstrom to Autolus' Board of
Directors, effective August 1, 2020. Dr Backstrom currently serves
as EVP, Head of Research & Development at Acceleron Pharma Inc.
and prior to that served as CMO and Head of Regulatory Affairs at
Celgene Corporation.
Key Upcoming Clinical Milestones:
-- AUTO1 updates in 2021 on ALLCAR19 in patients with r/r B-NHL
and longer term follow up of the fully enrolled r/r aALL
cohort.
-- AUTO1 - Currently enrolling Phase 1b/2 pivotal study (FELIX)
in r/r adult ALL patients with data expected in 2022.
-- Updates on Phase 1 programs AUTO1/22 in pediatric ALL, as
well as AUTO4 in TRBC1+ Peripheral TCL, in 2021.
-- Phase 1 trials are expected to be initiated in 2021 with
AUTO1 in Primary CNS Lymphoma, AUTO5 in TRBC2+ Peripheral TCL,
AUTO6NG in Neuroblastoma, and AUTO8 in Multiple Myeloma.
-- First exploratory allogeneic program expected to enter the clinic in H1 2021.
Financial Results for the Quarter and Year Ended December 31,
2020
Cash at December 31, 2020 totaled $153.3 million, as compared to
$210.6 million at December 31, 2019. In January 2021, the company
sold 1.7 million ADSs under its Open Market Sales Agreement(SM)
with Jefferies LLC as sales agent, resulting in net proceeds of
$15.3 million and in February 2021, the company conducted a public
offering of 16,428,572 ADSs representing 16,428,572 ordinary
shares, including the exercise in full by the underwriters of their
option to purchase an additional 2,142,857 ADSs, at a public
offering price of $7.00 per ADS and net proceeds of $108.1
million.
Net total operating expenses for the twelve months ended
December 31, 2020 were $168.1 million, net of grant income and
license revenue of $1.7 million, as compared to net operating
expenses of $146.1 million, net of grant income of $2.9 million,
for the same period in 2019.
Research and development expenses increased to $134.9 million
for the year ended December 31, 2020 from $105.4 million for the
year ended December 31, 2019. Cash costs, which exclude
depreciation and amortization as well as share-based compensation,
increased to $116.9 million from $83.4 million. The increase in
research and development cash costs of $33.5 million consisted
primarily of (i) an increase of $8.8 million in compensation and
employment related costs, net of lower travel costs, due to an
increase in employee headcount to support the advancement of our
product candidates in clinical development and lessened travel due
to the COVID-19 pandemic, (ii) an increase of $14.4 million in
project expenses as a consequence of the advancement of our
clinical portfolio which includes research and process development
and manufacturing activities necessary to prepare, activate, and
monitor clinical trial programs, (iii) an increase of $6.0 million
in facilities costs related to the commencement of a lease for an
additional manufacturing suite and the continued scaling of
manufacturing operations, (iv) an increase of $4.0 million in IT
infrastructure and support for information systems related to the
conduct of clinical trials and manufacturing operations, (v) an
increase of $0.5 million related to legal fees and (vi) an increase
of $1.7 million related to cell logistics, which is offset by a
reduction in materials purchases of $0.7 million and license fees
of $1.1 million.
Non-cash Research & Development costs decreased to $18.1
million for the year ended December 31, 2020 from $22.0 million for
the year ended December 31, 2019. The $3.9 million decrease is
related to a decrease of $4.8 million share-based compensation
expense as a result of a lower fair value of stock options
recognized in the period, offset by a $0.9 million increase in
depreciation.
General and administrative expenses decreased to $35.0 million
for the year ended December 31, 2020 from $39.5 million for the
year ended December 31, 2019. Cash costs, which exclude
depreciation as well as share-based compensation increased to $27.4
million from $26.6 million. There were increases of $1.3 million
related to D&O insurance costs and intellectual property and
$0.1 million of facilities cost, offset by decreases of $0.5
million of compensation and other employment related costs and $0.1
million in general office expense.
Non-cash General and Administrative costs decreased to $7.6
million for the year ended December 31, 2020 from $12.9 million for
the year ended December 31, 2019. The decrease of $5.3 million is
mainly attributed to lower share-based compensation expenses as a
result of the lower fair value of share options recognized during
the period.
Interest income decreased to $0.5 million for the year ended
December 31, 2020 from $2.5 million for the year ended December 31,
2019. This decrease is due to the lower cash balances held during
the year combined with lower interest rates for cash held on
deposit. Other income decreased to $1.4 million for the year ended
December 31, 2020 from $4.5 million for the year ended December 31,
2019 primarily due to a weakening of the U.S. dollar exchange rate
relative to the pound sterling. The decrease of $4.6 million in the
year ended December 31, 2020 was offset by lease termination gains
of $1.5 million.
The Income tax benefit increased to $24.2 million for the year
ended December 31, 2020 from $15.2 million for the year ended
December 31, 2019 due to additional U.K. research and development
tax credits receivable from HMRC. Research and development credits
are obtained at a maximum rate of 33.35% of our qualifying research
and development expenses, and the increase in the net credit was
primarily attributable to an increase in the company's eligible
research and development expenses.
Net loss attributable to ordinary shareholders was $142.1
million for the twelve months ended December 31, 2020, compared to
$123.8 million for the same period in 2019. The basic and diluted
net loss per ordinary share for the twelve months ended December
31, 2020 totaled $(2.76) compared to a basic and diluted net loss
per ordinary share of $(2.88) for the twelve months ended December
31, 2019.
Autolus estimates that its current cash on hand, which includes
the recent financings in January and February 2021, will extend the
Company's runway into H1 2023.
Management will host a conference call and webcast at 8:30 am
ET/1:30 pm GMT to discuss the company's financial results and
provide a general business update. To listen to the webcast and
view the accompanying slide presentation, please go to the events
section of Autolus' website
The call may also be accessed by dialing (866) 679-5407 for U.S.
and Canada callers or (409) 217-8320 for international callers.
Please reference conference ID 2268057. After the conference call,
a replay will be available for one week. To access the replay,
please dial (855) 859-2056 for U.S. and Canada callers or (404)
537-3406 for international callers. Please reference conference ID
2268057.
About Autolus Therapeutics plc
Autolus is a clinical-stage biopharmaceutical company developing
next-generation, programmed T cell therapies for the treatment of
cancer. Using a broad suite of proprietary and modular T cell
programming technologies, the company is engineering precisely
targeted, controlled and highly active T cell therapies that are
designed to better recognize cancer cells, break down their defense
mechanisms and eliminate these cells. Autolus has a pipeline of
product candidates in development for the treatment of
hematological malignancies and solid tumors. For more information
please visit www.autolus.com .
About AUTO1
AUTO1 is a CD19 CAR T cell investigational therapy designed to
overcome the limitations in clinical activity and safety compared
to current CD19 CAR T cell therapies. Designed to have a fast
target binding off-rate to minimize excessive activation of the
programmed T cells, AUTO1 may reduce toxicity and be less prone to
T cell exhaustion, which could enhance persistence and improve the
ability of the programmed T cells to engage in serial killing of
target cancer cells. In collaboration with our academic partner,
UCL, AUTO1 is currently being evaluated in a Phase 1 clinical trial
in adult ALL and B-NHL. The company has also progressed AUTO1 to
the FELIX study, a potential pivotal study.
About AUTO1 FELIX study
The FELIX study is enrolling adult patients with relapsed /
refractory ALL. The trial has a short Phase 1b component prior to
proceeding to a single arm Phase 2 clinical trial. The primary
endpoint is overall response rate, and the key secondary endpoints
include duration of response, MRD negative CR rate and safety. The
trial will enroll approximately 100 patients across 30 of the
leading academic and non-academic centers in the United States,
United Kingdom and Europe.
About AUTO3
AUTO3 is a programmed T cell investigational therapy containing
two independent chimeric antigen receptors targeting CD19 and CD22
that have each been independently optimized for single target
activity. AUTO3 is designed to combine a favorable safety profile
with a reduced risk of relapse due to single antigen loss. AUTO3 is
has been tested in diffuse large B cell lymphoma in the ALEXANDER
clinical trial demonstrating a high level of clinical activity with
a favorable safety profile. The ALEXANDER study included a
20-patient out-patient cohort and demonstrated feasibility of AUTO3
delivery in an outpatient setting.
About AUTO4
AUTO4 is a programmed T cell product candidate in clinical
development for T cell lymphoma, a setting where there are
currently no approved programmed T cell therapies. AUTO4 is
specifically designed to target TRBC1 derived cancers, which
account for approximately 40% of T cell lymphomas, and is a
complement to the AUTO5 T cell product candidate, which is in
pre-clinical development.
About AUTO5
AUTO5 is a programmed T cell product candidate in pre-clinical
development for T cell lymphoma, a setting where there are
currently no approved programmed T cell therapies. AUTO5 is
specifically designed to target TRBC2 derived cancers, which
account for approximately 60% of T cell lymphomas, and is a
complement to the AUTO4 T cell product candidate currently in
clinical development.
About AUTO6NG
AUTO6NG is a next generation programmed T cell product candidate
in pre-clinical development. AUTO6NG builds on preliminary proof of
concept data from AUTO6, a CAR targeting GD2-expression cancer cell
currently in clinical development for the treatment of
neuroblastoma. AUTO6NG incorporates additional cell programming
modules to overcome immune suppressive defense mechanisms in the
tumor microenvironment, in addition to endowing the CAR T cells
with extended persistence capacity. AUTO6NG is currently in
pre-clinical development for the potential treatment of both
neuroblastoma and other GD2-expressing solid tumors.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements are statements that are not historical facts, and in
some cases can be identified by terms such as "may," "will,"
"could," "expects," "plans, " "anticipates," and "believes." These
statements include, but are not limited to, statements regarding
Autolus' refocused business strategy, including specifically on the
development of the AUTO1 program; the future clinical development,
efficacy, safety and therapeutic potential of its product
candidates, including progress, expectations as to the reporting of
data, conduct and timing and potential future clinical activity and
milestones; expectations regarding the initiation, design and
reporting of data from clinical trials ; the development of
Autolus' pipeline of next generation programs, including for solid
tumor indications, in collaboration with its academic partners,
including expectations as to the reporting of data, conduct and
timing; the efficacy, safety and therapeutic potential of AUTO3 and
ability for Autolus to obtain a partner for next stages of clinical
development; needs for additional funding and ability to raise
additional capital; Autolus' ability to attract and retain
qualified employees and key personnel; the restructuring program
and Autolus' expected cash savings as a result of the restructuring
program and operational changes; and Autolus' expected cash runway.
Any forward-looking statements are based on management's current
views and assumptions and involve risks and uncertainties that
could cause actual results, performance or events to differ
materially from those expressed or implied in such statements.
These risks and uncertainties include, but are not limited to, the
risks that Autolus' preclinical or clinical programs do not advance
or result in approved products on a timely or cost effective basis
or at all; the results of early clinical trials are not always
being predictive of future results; the cost, timing and results of
clinical trials; that many product candidates do not become
approved drugs on a timely or cost effective basis or at all; the
ability to enroll patients in clinical trials; possible safety and
efficacy concerns; and the impact of the ongoing COVID-19 pandemic
on Autolus' business. For a discussion of other risks and
uncertainties, and other important factors, any of which could
cause Autolus' actual results to differ from those contained in the
forward-looking statements, see the section titled "Risk Factors"
in Autolus' Annual Report on Form 20-F filed with the Securities
and Exchange Commission on March 3, 2020, as amended, as well as
discussions of potential risks, uncertainties, and other important
factors in Autolus' subsequent filings with the Securities and
Exchange Commission. All information in this press release is as of
the date of the release, and Autolus undertakes no obligation to
publicly update any forward-looking statement, whether as a result
of new information, future events, or otherwise, except as required
by law.
Contact:
Lucinda Crabtree, PhD
Vice President, Investor Relations and Corporate
Communications
+44 (0) 7587 372 619
l.crabtree@autolus.com
Julia Wilson
+44 (0) 7818 430877
j.wilson@autolus.com
Susan A. Noonan
S.A. Noonan Communications
+1-212-966-3650
susan@sanoonan.com
Financial Results for the Year Ended December 31, 2020
Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
For the Year Ended For the three-months For the
December 31, ended December Year Ended
31, September
30,
2020 2019 2018 2018
------------- ------------ ---------------------- ---------------
Grant income $ 1,473 $ 2,908 $ 296 $ 1,407
License revenue 242 - - -
Operating expenses:
Research and development (134,888) (105,418) (17,713) (36,150)
General and administrative (34,972) (39,452) (7,593) (22,790)
Loss on impairment of leasehold
improvements - (4,102) - -
------------- ------------ ---------------------- -------------
Total operating expenses, net (168,145) (146,064) (25,010) (57,533)
Other income (expense):
Interest income 536 2,542 660 1,532
Other income (expense) 1,352 4,514 1,097 3,970
------------- ------------ ---------------------- -------------
Total other income, net 1,888 7,056 1,757 5,502
------------- ------------ ---------------------- -------------
Net loss before income tax (166,257) (139,008) (23,253) (52,031)
Income tax benefit 24,163 15,159 2,605 7,280
------------- ------------ ---------------------- -------------
Net loss attributable to ordinary
shareholders (142,094) (123,849) (20,648) (44,751)
Other comprehensive (loss) income:
Foreign currency exchange translation
adjustment 2,830 6,797 (5,568) (6,071)
------------- ------------ ---------------------- -------------
Total comprehensive loss (139,264) (117,052) (26,216) (50,822)
============= ============ ====================== =============
Basic and diluted net loss per
ordinary share $ (2.76) $ (2.88) $ (0.52) $ (1.42)
Weighted-average basic and diluted
ordinary shares 51,558,075 43,065,542 39,366,634 31,557,034
Consolidated Balance Sheets
(In thousands, except share and per share amounts)
December 31,
2020 2019
----------- -------------
Assets
Current assets:
Cash $ 153,299 $ 210,643
Restricted cash 786 787
Prepaid expenses and other current assets 42,899 37,826
----------- -----------
Total current assets 196,984 249,256
Non-current assets:
Property and equipment, net 38,046 28,164
Prepaid expenses and other non-current assets 3,033 -
Right of use asset, net 51,637 23,409
Long-term deposits 2,625 2,040
Deferred tax asset 1,754 410
Intangible assets, net 158 254
----------- -----------
Total assets $ 294,237 $ 303,533
======= =======
Liabilities and shareholders' equity
Current liabilities:
Accounts payable 2,263 1,075
Accrued expenses and other liabilities 27,781 21,398
Lease liability 3,590 2,511
----------- -----------
Total current liabilities 33,634 24,984
Non-current liabilities:
Lease liability 50,571 23,710
----------- -----------
Total liabilities 84,205 48,694
Shareholders' equity:
Ordinary shares, $0.000042 par value; 200,000,000 shares
authorized at December 31, 2020 and 2019, 52,346,231
and 44,983,006 shares issued and outstanding at December
31, 2020 and 2019 3 2
Deferred shares, GBP0.00001 par value; 34,425 shares
authorized, issued and outstanding at December 31,
2020 and 2019 - -
Deferred B shares, GBP0.00099 par value; 88,893,548
shares authorized, issued and outstanding at December
31, 2020 and 2019 118 118
Deferred C shares, GBP0.000008 par value; 1 share authorized,
issued and outstanding at December 31, 2020 and 2019 - -
Additional paid-in capital 595,016 500,560
Accumulated other comprehensive loss (5,861) (8,691)
Accumulated deficit (379,244) (237,150)
----------- -----------
Total shareholders' equity 210,032 254,839
----------- -----------
Total liabilities and shareholders' equity $ 294,237 $ 303,533
======= =======
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
PFUFIFVAVSISIIL
(END) Dow Jones Newswires
March 04, 2021 07:10 ET (12:10 GMT)
Syncona (LSE:SYNC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Syncona (LSE:SYNC)
Historical Stock Chart
From Apr 2023 to Apr 2024
